Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Hansoh Pharma
Biotech
Hansoh heralds China’s move from ‘follower’ to ‘frontrunner’
Hansoh gave a bullish assessment of China’s biopharma role, arguing that it is “fully transitioning from the ‘follower’ to the ‘frontrunner’ phase.”
Nick Paul Taylor
Aug 26, 2026 9:33am
GSK partner Hansoh reports another phase 3 win for priority ADC
Jul 28, 2026 8:20am
GSK sees phase 3 win for Hansoh-partnered ADC as justifying hype
Jul 10, 2026 8:39am
Tortugas comes out of shell with $106M, 4 ph. 2-stage neuro meds
Apr 21, 2026 10:41am
GSK CEO’s ‘scientific courage’ propels ADC toward ph. 3 tests
Apr 12, 2026 10:10am
Regeneron's obesity drug shows Zepbound-like efficacy in phase 3
Mar 9, 2026 8:25am
